Format

Send to

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem. 2013 Nov 15;21(22):7210-5. doi: 10.1016/j.bmc.2013.08.033. Epub 2013 Aug 28.

Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases.

Author information

1
Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Box 100245, Gainesville, FL 32610, USA.

Abstract

Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes that catalyze the reversible hydration of carbon dioxide and bicarbonate. Their pivotal role in metabolism, ubiquitous nature, and multiple isoforms (CA I-XIV) has made CAs an attractive drug target in clinical applications. The usefulness of CA inhibitors (CAIs) in the treatment of glaucoma and epilepsy are well documented. In addition several isoforms of CAs (namely, CA IX) also serve as biological markers for certain tumors, and therefore they have the potential for useful applications in the treatment of cancer. This is a structural study on the binding interactions of the widely used CA inhibitory drugs brinzolamide (marketed as AzoptĀ®) and dorzolamide (marketed as TrusoptĀ®) with CA II and a CA IX-mimic, which was created via site-directed mutagenesis of CA II cDNA such that the active site resembles that of CA IX. Also the inhibition of CA II and CA IX and molecular docking reveal brinzolamide to be a more potent inhibitor among the other catalytically active CA isoforms compared to dorzolamide. The structures show that the tail end of the sulfonamide inhibitor is critical in forming stabilizing interactions that influence tight binding; therefore, for future drug design it is the tail moiety that will ultimately determine isoform specificity.

KEYWORDS:

BRZ; Brinzolamide; CA; CA II; CA IX; DRZ; Dorzolamide; Human carbonic anhydrase; brinzolamide; carbonic anhydrase; dorzolamide; human carbonic anhydrase II; human carbonic anhydrase IX

PMID:
24090602
DOI:
10.1016/j.bmc.2013.08.033
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center